Could AxoGen, Inc. (AXGN) See a Reversal After Breaking Its 52-Week High?

March 22, 2018 - By Marguerite Chambers

The stock of AxoGen, Inc. (NASDAQ:AXGN) hit a new 52-week high and has $43.00 target or 9.00 % above today’s $39.45 share price. The 8 months bullish chart indicates low risk for the $1.36 billion company. The 1-year high was reported on Mar, 22 by If the $43.00 price target is reached, the company will be worth $122.49M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.13% or $0.05 during the last trading session, reaching $39.45. About 66,082 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since March 22, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on May, 3. They expect $-0.11 earnings per share, 0.00 % or $0.00 from last year’s $-0.11 per share. After $-0.07 actual earnings per share reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts 57.14 % negative EPS growth.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen has $38.0 highest and $4 lowest target. $28.25’s average target is -28.39% below currents $39.45 stock price. AxoGen had 21 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given on Tuesday, November 22 by Lake Street. The firm has “Outperform” rating by Wedbush given on Friday, August 28. The firm earned “Buy” rating on Monday, August 21 by Cantor Fitzgerald. Wedbush maintained it with “Buy” rating and $27.0 target in Tuesday, November 21 report. The firm earned “Buy” rating on Monday, September 11 by Roth Capital. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given on Monday, January 8 by Cantor Fitzgerald. The rating was maintained by JMP Securities with “Market Outperform” on Thursday, March 1. The firm earned “Hold” rating on Thursday, November 3 by Lake Street. The firm has “Outperform” rating by Leerink Swann given on Thursday, November 2. The firm earned “Buy” rating on Friday, March 2 by Lake Street.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.36 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.